Induction of the mitochondria-mediated apoptosis in human esophageal cancer cells by DS2, a newly synthetic diterpenoid analog, is regulated by Bax and caused by generation of reactive oxygen species

Oncotarget

Volumn 7, Issue 52, 2016, Pages 86211-86224

  Ma, Yong Cheng ^a   Ke, Yu ^a   Zi, Xiaolin ^b,c   Zhao, Fei ^a   Yuan, Lin ^a   Zhu, Ying Li ^a   Fan, Xia Xia ^a   Zhao, Ning Min ^a   Li, Qiao Yan ^a   Qin, Yu Hua ^a   Liu, Hong Min ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bax; Ent kaurene diterpenoid derivative; Esophageal squamous cell carcinoma; Mitochondrion; ROS

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CASPASE 3; CASPASE 9; CYTOCHROME C; DS 2; PROTEIN BAX; PROTEIN P21; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; BAX PROTEIN, HUMAN; KAURANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVATION; ESOPHAGEAL CANCER CELL LINE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ESOPHAGUS TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; DITERPENES, KAURANE; ESOPHAGEAL NEOPLASMS; HUMANS; MITOCHONDRIA; REACTIVE OXYGEN SPECIES;

EID: 85007418066     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13367     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90
2. Zhao CL, Yu WJ, Gao ZQ, Li WT, Gao W, Yang WW, Feng WG, Ju JY. Association of BCSC-1 with human esophageal squamous cell carcinoma. Neoplasma. 2015; 62:765-769
3. Ning ZH, Zhao W, Li XD, Chen LJ, Xu B, Gu WD, Shao YJ, Xu Y, Huang J, Pei HL, Jiang JT. The status of perineural invasion predicts the outcomes of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015; 8:6881-6890
4. Barnes EC, Kumar R, Davis RA. The use of isolated natural products as scaffolds for the generation of chemically diverse screening libraries for drug discovery. Nat Prod Rep. 2016; 33:372-381
5. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015; 14:111-129
6. Ding CY, Zhang YS, Chen HJ, Yang ZD, Wild C, Chu LL, Liu HL, Shen Q, Zhou J. Novel nitrogen-enriched oridonin analogs with thiazole-fused a-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J Med Chem. 2013; 56:5048-5058
7. Sun HD, Huang SX, Han QB. Diterpenoids from isodon species and their biological activities. Natural Product Reports. 2006; 23:673-698
8. Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t (8;21) leukemia in vitro and in vivo. Blood. 2007; 109:3441-3450
9. Ma YC, Ke Y, Zi XL, Zhao W, Shi XJ, Liu HM. Jaridonin, a novel eiterpenoid from isodon rubescens, induces reactive oxygen species-mediated apoptosis in esophageal cancer cells. Current Cancer Drug Targets. 2013; 13:611-624
10. Wang L, Zhao WL, Yan JS, Liu P, Sun HP, Zhou GB, Weng ZY, Wu WL, Weng XQ, Sun XJ, Chen Z, Sun HD, Chen SJ. Eriocalyxin B induces apoptosis of t (8;21) leukemia cells through NF-jB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death and Differentiation. 2007; 14:306-317
11. Ding CY, Zhang YS, Chen HJ, Yang ZD, Wild C, Ye N, Ester CD, Xiong AL, White MA, Shen Q, Zhou J. Oridonin ring a-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J Med Chem. 2013; 56:8814-8825
12. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera SS, Ikejima T. Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys. 2009; 490:70-75
13. Qi XL, Zhang DR, Xu X, Feng FF, Ren GJ, Chu QQ, Zhang Q, Tian KL. Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int J Nanomedicine. 2012; 7:1793-1804
14. Bao RF, Shu YJ, Wu XS, Weng H, Ding Q, Cao Y, Li ML, Mu JS, Wu WG, Ding QC, Tan ZJ, Liu TY, Jiang L, et al. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer. 2014; 14:217
15. Shi M, Lu XJ, Zhang J, Diao H, Li G, Xu L, Wang T, Wei J, Meng W, Ma JL, Yu H, Wang YG. Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53-and caspase-3-mediated mechanisms. Oncotarget. 2016; 7:22623-22631. doi: 10.18632/oncotarget.8033
16. Cheng Y, Qiu F, Ikejima T. Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells. Autophagy. 2009; 5:430-431
17. Li Y, Wang Y, Wang SH, Gao YJ, Zhang XF, Lu CH. Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells. Med Oncol. 2015; 32:365
18. Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen M, Wang Y. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells. Am J Chin Med. 2013; 41:177-196
19. Ma YC, Su N, Shi XJ, Zhao W, Ke Y, Zi X, Zhao NM, Qin YH, Zhao HW, Liu HM. Jaridonin-induced G2/M phase arrest in human esophageal cancer cells is caused by reactive oxygen species-dependent Cdc2-tyr15 phosphorylation via ATM-Chk1/2-Cdc25C pathway. Toxicol Appl Pharm. 2015; 282:227-236
20. Fimognari C, Lenzi M, Hrelia P. Apoptosis induction by sulfur-containing compounds in malignant and nonmalignant human cells. Environmental and Molecular Mutagenesis. 2009; 50:171-189
21. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998; 281:1309-1312
22. Yan J, Pang YQ, Sheng JF, Wang YL, Chen J, Hu JH, Huang L, Li XS. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells. Biochemical Pharmacology. 2015; 97:51-61
23. Liu ZQ, Ding Y, Ye N, Wild C, Chen HY, Zhou J. Direct activation of Bax protein for cancer therapy. Med Res Rev. 2016; 36:313-341
24. Yang Y, Karakhanova S, Hartwig W, D'Haese JG, Philippov PP, Werner J, Bazhin AV. Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. J Cell Physiol. 2016; 231:2570-2581
25. Aranda A, Sequedo L, Tolosa L, Quintas G, Burello E, Castell JV, Gombau L. Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay: a quantitative method for oxidative stress assessment of nanoparticle-treated cells. Toxicology In Vitro. 2013; 27:954-963
26. Yang J, Wang WG, Wu HY, Du X, Li XN, Li Y, Pu JX, Sun HD. Bioactive Enmein-Type ent-Kaurane Diterpenoids from Isodon phyllostachys. J Nat Prod. 2016; 79:132-140
27. Owona BA, Schluesener HJ. Molecular insight in the multifunctional effects of oridonin. Drugs R D. 2015; 15:233-244
28. Wu J, Ding Y, Chen CHZ, Zhou ZM, Ding CY, Chen HY, Zhou J, Chen CS. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. Cancer Letters. 2016:380:393-402
29. Chen W, Zhou JC, Wu KJ, Huang J, Ding Y, Yun EJ, Wang B, Ding CY, Hernandez E, Santoyo J, Chen HY, Lin H. Sagalowsky A, et al. Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic oridonin analogues. Oncotarget. 2016; [E-pub ahead of print]. doi: 10.18632/oncotarget.10863
30. Ding Y, Ding C, Ye N, Liu Z, Wold EA, Chen H, Wild C, Shen Q, Zhou J. Discovery and development of natural product oridonin-inspired anticancer agents. Eur J Med Chem. 2016; 122:102-117
31. Brenner D, Mak TW. Mitochondrial cell death effectors. Curr Opin Cell Biol. 2009; 21:871-877
32. Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res. 2011; 17:4019-4030
33. Ling YH, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 nonsmall-cell lung cancer cells with epidermal growth factor receptor L858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol. 2008; 74:793-806
34. Souers AJ, Leverson JD, Boghaert ER, SAckler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19:202-208
35. Park MT, Lee SJ. Cell cycle and cancer. Journal of Biochemistry and Molecular Biology. 2003; 36:60-65
36. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Current Pharmaceutical Design. 2000; 6:379-392
37. Li X, Li X, J. Wang, Z. Ye, J.C. Li. Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci. 2012; 8:901-912
38. Zhang JH, Kang N, Qiu F, Chen S, Tashiro S, Onodera S, Ikejima T. Induction of G/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. J Nat Prod. 2010; 73:1058-1063
39. Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016; 42:63-71
40. Chen WQ, Zou P, Zhao ZW, Weng QY, Chen X, Ying SL, Ye QQ, Wan Z, Ji JS, Liang G. Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation. Oncotarget. 2016; 7:16593-16609. doi: 10.18632/oncotarget.7565
41. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12:931-947
42. Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets CA, Kopelovich L, Athar M. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 2010; 70:6566-6576
43. Sankpal UT, Nagaraju GP, Gottipolu SR, Hurtado M, Jordan CG, Simecka JW, Shoji M, EI-Rayes B, Basha R. Combination of Tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species. Oncotarget. 2016; 7:3186-3200. doi: 10.18632/oncotarget.6553